Nectar Lifesciences Share Price Today

Nectar Lifesciences shareholders approve FY26 financials and director reappointments

Shareholders adopted standalone and consolidated financial statements for FY26 with 99.986% votes in favor. Sanjiv Goyal reappointed as director; Dr. Kuldip Kumar Bhasin and Dr. Indu Pal Kaur reappointed as Independent Directors for second terms. Dr. Gunmala Suri appointed as Non-Executive Non-Independent Director effective August 15, 2026. Public shareholders voted against director appointments, but promoter majority ensured all resolutions passed.

Nectar Lifesciences CGST case remanded for fresh consideration

The Hon'ble High Court of Punjab and Haryana remanded a CGST dispute involving Nectar Lifesciences back to the Appellate Authority for fresh consideration on September 24, 2026. The Principal Commissioner of CGST Commissionerate, Ludhiana, filed a civil writ petition challenging the Appellate Authority's order dated May 27, 2025. The earlier appellate order had dropped a ₹89.32 crore demand and remanded a ₹6.24 crore demand for de novo adjudication. The Appellate Authority had confirmed ineligible ITC of ₹17.06 lakh (CGST ₹8.53 lakh and SGST ₹8.53 lakh) with an equivalent penalty. The company states the final quantum of liability is presently not ascertainable and reserves the right to appeal before the Hon'ble Tribunal if required.

Nectar Lifesciences corrects AGM cut-off date error in revised proceedings

Nectar Lifesciences issued revised AGM proceedings to correct a cut-off date error. Shareholders approved FY26 financials and reappointed key board members. Promoter group voted 100% in favour of all five resolutions. Statutory auditors gave unqualified opinion on FY25-26 results.

Nectar Lifesciences schedules 31st AGM for September 18, 2026

31st AGM scheduled for September 18, 2026. Meeting conducted via video conference. Remote e-voting runs from September 15 to 17. Annual Report for FY26 available online.

Nectar Lifesciences reports ₹2,929 crore net loss in FY26 amid pharma exit

Nectar Lifesciences reported a ₹2,928.85 crore net loss in FY26, driven by a ₹520.95 crore investment loss and discontinued operations, despite a ₹1,633.73 crore gain from selling its pharma business. The company is now debt-free with ₹1,081.30 crore in cash and has entered the real estate sector via Avensis Exports Private Limited.

Nectar Lifesciences Q1 Results: Consolidated loss narrows to ₹157.2 crore

Nectar Lifesciences reported a Q1FY27 consolidated net loss of ₹157.2 crore, down significantly from ₹632.3 crore in Q1FY26. Revenue from continuing operations rose to ₹44.2 crore. The improvement is largely driven by discontinued operations, which swung from a ₹6,331.9 crore loss to a ₹32.1 crore profit.